Healthier living seems to be everywhere we look. From more health-conscious dietary options quickly replacing fast food chains in many areas of the world to a global public more dedicated to maintaining a regular exercise regimen, there’s been a paradigm shift with regard to the way we treat our bodies. Of course, a society’s goal is always to uncover new ways for its people to live healthier lives for as long as possible.
Into this foray has come Elysium Health, a consumer health company that seeks to help people live healthier, longer. Working directly with the world’s leading clinicians and scientists, Elysium Health is making a name for itself, translating advances in technology and science into effective, scientifically sound health products that actually work. The brainchild of Dr. Leonard Guarente, the director of the Paul F. Glenn Laboratory for Biology of Aging Research at MIT, Elysium Health is a new kind of health company.
At the heart of Elysium Health’s mission is Basis, a daily supplement designed to support well-being at the cellular level by increasing and sustaining levels of NAD+ in human cells. Basis is the culmination of more than 25 years of aging research. NAD+ is a coenzyme essential to many biological processes, including energy creation, DNA maintenance, and circadian rhythms. NAD+ declines as we get older and those functions break down. Basis, which contains a pair of compounds: nicotinamide riboside (an NAD+ precursor) and pterostilbene, is clinically proven to increase NAD+ levels safely and sustainably by an average of 40 percent.
Basis is recommended for long-term use by adults of all ages. Basis contains no animal products, artificial colors, or artificial flavors. What’s more, the ingredients in Basis have been tested for safety and are produced in facilities that meet FDA requirements. The supplement also undergoes rigorous third-party purity testing.
Elysium Health recommends taking two Basis of capsules each morning, with or without food; each jar of the supplement contains a 30-day supply. According to company representatives, the most popular subscription for the supplement is for six months, which runs $270, or $45 per month. A one-year subscription costs $480, or $40 per month and an ongoing subscription costs $50 per month. A one-off bottle is $60.
“As we age, NAD+ levels in our cells decline, and our trial results indicate that Basis increases NAD+ levels in a sustained way,” says Dr. Guarente. “Since NAD+ is involved in hundreds of critical cellular processes, we believe it’s a vitally important component to optimizing our cellular health as we get older.”
Additional information about Elysium Health Can be found at www.ElysiumHealth.com.
Clay Siegall is a successful entrepreneur and investor. Clay is famed for his venture in biotechnology. He is the one who co-founded Seattle Genetics. Presently he serves as the CEO and the president of the drug company that he co-founded. The firm develops drugs with antibodies that target treatment of cancer patient.
Clay Siegall has diverse and excellent experience in biotechnology. In his career course, he worked with National Institute of Health, Bristol-Myers Squibb Pharmaceutical Research Institute, and National Cancer Institute. Clay Siegall has the track of record and excellent knowledge in healthcare. He was also a board member of directors in Alder BioPharmaceutical. Therefore his idea of coming up with Seattle Genetics was a brilliant move as an investor.
Dr. Clay Siegall has helped Seattle Genetics Company to raise over $ 675 million finances and in developing various antibodies drug pipelines that aim at curing the cancer diseases. Seattle Genetics is renowned Oncology and multi pharmaceutical product in the whole world. It focusses on the production of the antibody-drug conjugate(ADC) which targets human antigens in response to release antibodies in the human immune system that fights against diseases. Consequently, the antibodies attack the cancer cell from inside and release toxic substances which kill the cancer cell. The use of ADC is more advisable as it reduces the danger of exposing healthy human cells to radiations through other therapies like chemotherapy or any other traditional method.
The company developed Adcetris cancer drug which treats lymphatic system cancer that might spread to other body organ and cause severe pain and damage to tissues. 33A is the second in the list which cures myeloid leukemia, the third one is 22ME which targets cancer of the bladder or any other kind of urothelial cancer, and lastly, Seattle Genetics Company launched LIVI which targets the breast cancer. If you have a cancer patient or you are suffering from the disease make an effort and consider using Seattle Genetics products.
Clay Siegall received Ph.D. in Genetics from Washington University and holds B.S in Zoology from the University of Maryland. He has written and published more than seventy publications plus fifteen patents.